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Ribosomal S6 kinase 1 (RSK1) activation requires signals
dependent on and independent of the MAP kinase ERK
Stephanie A. Richards, Joyce Fu, Angela Romanelli, Akiko Shimamura
and John Blenis
Background: The rsk1 gene encodes the 90 kDa ribosomal S6 kinase 1
(RSK1) protein, which contains two kinase domains. RSK1, which is involved in
regulating cell survival and proliferation, lies at the end of the signaling cascade
mediated by the extracellular signal-regulated kinase (ERK) subfamily of
mitogen-activated protein (MAP) kinases. ERK activation and subsequent
phosphorylation of the RSK1 carboxy-terminal catalytic loop stimulates
phosphotransferase activity in the RSK1 amino-terminal kinase domain. When
activated, RSK1 phosphorylates both nuclear and cytoplasmic substrates
through this amino-terminal catalytic domain. It is thought that stimulation of the
ERK/MAP kinase pathway is sufficient for RSK1 activation, but how ERK
phosphorylation activates the RSK1 amino-terminal kinase domain is not known. 
Results: The individual isolated RSK1 kinase domains were found to be under
regulatory control. In vitro kinase assays established that ERK phosphorylates
RSK1 within the carboxy-terminal kinase domain, and the phosphoinositide-
dependent kinase 1 (PDK1) phosphorylates RSK1 within the amino-terminal
kinase domain. In transiently transfected HEK 293E cells, PDK1 alone
stimulated phosphotransferase activity of an isolated RSK1 amino-terminal
kinase domain. Nevertheless, activation of full-length RSK1 in the absence of
serum required activation by both PDK1 and ERK.
Conclusions: RSK1 is phosphorylated by PDK1 in the amino-terminal kinase-
activation loop, and by ERK in the carboxy-terminal kinase-activation loop.
Activation of phosphotransferase activity of full-length RSK1 in vivo requires
both PDK1 and ERK. RSK1 activation is therefore regulated by both the
mitogen-stimulated ERK/MAP kinase pathway and a PDK1-dependent pathway. 
Background
Mitogenic stimuli activate the ribosomal S6 kinase 1
(RSK1) through the pathway involving the extracellular
signal-regulated kinase (ERK) subfamily of mitogen-acti-
vated protein (MAP) kinases. Generation of the GTP-
bound form of Ras initiates a kinase cascade whereby Raf
kinases activates MAP kinase kinase (MEK), which acti-
vates ERK1/ERK2, which in turn phosphorylates RSK1
(reviewed in [1]). RSK1 is a serine/threonine kinase with
two distinct kinase domains, both of which are catalyti-
cally functional [2]. The  carboxy-terminal kinase domain
is believed to be involved in autophosphorylation, a criti-
cal feature of RSK1 activation, whereas the amino-termi-
nal kinase domain is responsible for the phosphorylation
of all exogenous substrates tested. 
RSK is cytoplasmic, but it can translocate to the nucleus
upon mitogenic stimulation [3]. Activated RSK has both
cytoplasmic and nuclear substrates. Phosphorylation of the
apoptotic protein BAD by RSK can protect cells from
BAD-mediated cell death (A.S., unpublished observations).
RSK also phosphorylates IκBα, the inhibitor of the tran-
scription factor NF-κB, inducing degradation of IκBα and
allowing NF-κB to translocate to the nucleus [4]. RSK
plays an important role in nuclear signaling by phosphory-
lating various transcription factors, including the cyclic
AMP (cAMP) response element binding protein (CREB)
[5,6] and c-Fos [7,8]; RSK therefore has a role in transcrip-
tional regulation. RSK has also been implicated in cell-
cycle regulation. In Xenopus extracts RSK phosphorylates
and downregulates Myt1, a p34cdc2 inhibitory kinase [9].
Downregulation of Myt1 leads to activation of
cyclin B–p34cdc2 kinase and cell-cycle progression. There-
fore, RSK has been implicated in a myriad of cellular
processes, but its cellular role and substrate(s) remain
unclear. The diversity of its substrates suggests that RSK
may participate in cell proliferation and differentiation
through multiple pathways.
Other than the requirements for ERK and autophosphory-
lation, relatively little is known about the mechanism of
RSK regulation. The presence of two active kinase domains
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within the enzyme undoubtedly increases the complexity
of studying this regulation. Six phosphorylation sites have
been identified in RSK1, two of which are basally phospho-
rylated, and four of which are phosphorylated upon mitogen
stimulation [10]. Among the mitogen-responsive sites are a
putative ERK phosphorylation site in the RSK1 carboxyl
terminus [11] and a putative RSK1 autophosphorylation site
in the linker region between the two RSK1 kinase domains
[12]. While sequence comparison suggests that the remain-
ing sites may be ERK or RSK1 phosphorylation sites, it is
possible that they are phosphorylated by other kinases.
ERK alone is not capable of fully activating RSK1 in vitro
[13], suggesting that additional input(s) may be required for
full RSK1 activation.
The RSK amino-terminal kinase domain has homology to
other kinase domains, including those in cAMP-depen-
dent protein kinase A (PKA) and p70 S6 kinase 1 (p70S6K1)
[14]. An important regulatory enzyme for PKA and p70S6K1
is phosphoinositide-dependent kinase 1 (PDK1). PDK1
phosphorylates a site in the activation loops of protein
kinase Bα (PKBα, also known as c-Akt) [15,16], various
protein kinase Cs  (PKCs) [17–19], PKA [20] and p70S6K1
[21,22]. PDK1 is a protein of 556 amino acids that contains
a kinase domain and a pleckstrin homology (PH) domain
[15,16]. The PH domain binds phosphatidylinositol 3,4,5-
trisphosphate (PtdIns(3,4,5)P3) generated by phospho-
inositide (PI) 3-kinases [23]. PDK1 is found in the cell
cytosol and at the plasma membrane [23,24].
We are interested in the regulation of the individual RSK1
kinase domains. Here, we report that each isolated RSK1
kinase domain can be activated. Surprisingly, PDK1 could
activate an isolated RSK1 amino-terminal kinase domain
in vivo, but activation of the full-length protein required
cooperation with the ERK/MAP-kinase pathway. We
propose a model for RSK1 activation that incorporates reg-
ulatory inputs from the ERK/MAP-kinase pathway and
additional phosphorylation events.
Results
Activation of isolated RSK1 kinase domains
Studies in vitro have indicated that both RSK1 kinase
domains are active [2]. It has not, however, been deter-
mined whether or how each isolated kinase domain is acti-
vated in vivo. Because the regulation of each kinase
domain could be different, knowing whether the two
domains are independently activated would be useful in
identifying the requirements for activation of full-length
RSK1. Therefore, the RSK1 constructs D1, D1′ and D2
were generated (Figure 1). D1 and D1′ encode the amino-
terminal kinase domain, with the only difference being an
additional 56 amino acids in D1′. This additional
sequence includes Ser398, which is analogous to the
Ser380 residue in Xenopus RSK1 that has been found to be
an autophosphorylation site [12] and is phosphorylated
upon mitogen stimulation in rat RSK1 [10]. D2 encodes
the carboxy-terminal kinase domain (Figure 1). 
When expressed in HEK 293E cells and stimulated with
serum, D1′ was active towards the substrate, a fusion
protein between glutathione-S-transferase and a ribosomal
S6 protein peptide (GST–S6), whereas D1 was not
(Figure 2). Even in the absence of serum, D1′ exhibited a
significant level of basal activity. The K112R mutation
abolished D1′ phosphotransferase activity. Mobility shift-
ing of endogenous RSK indicated that the cells were
serum-stimulated; therefore the lack of phosphotransferase
activity in D1 was not due to lack of stimulation. These
data suggest that the additional amino acids are critical for
the activation of the RSK1 amino-terminal kinase domain. 
The isolated D2 kinase domain was also expressed in cells
(Figure 3a,b). In serum-stimulated cells, D2 was active
towards exogenous GST–D2 (K464R) and, interestingly,
D2 also underwent a significant amount of autophospho-
rylation (Figure 3c,d). Again, a K464R mutation reduced
kinase activity of this domain. 
Because of the known contribution of ERK to RSK activa-
tion, we examined the effect of blocking ERK activation on
the kinase activity of each isolated kinase domain
(Figure 4). Cells transfected with either HA–D1′ or HA–D2
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Figure 1
Constructs encoding full-length (FL) RSK, D1, D1′ and D2 were
generated. Each construct was fused at the 5′ end to sequences
encoding a triple hemagglutinin (HA) epitope tag. White boxes, kinase
domains; numbers, amino-acid positions; identified phosphorylation
sites are S239, T377, S381, S398, T590 and S749; diamonds,
inactivating mutations in each kinase domain. Amino-acid residues are
indicated in the single-letter amino-acid code. The RSK clone used
was avian RSK1, which encodes an avian-specific epitope between
amino-acid residues 37 and 54 (Av epitope).
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were treated with the MEK inhibitor PD098059 before
serum stimulation, and phosphotransferase activity was
measured. For HA–D1′, PD098059 treatment severely cur-
tailed serum-stimulated kinase activity towards GST–S6,
but had no effect on the electrophoretic mobility of HA–D1′
(Figure 4a). For HA–D2, PD098059 treatment also reduced
its phosphotransferase activity, both towards an exogenous
substrate and its autophosphorylation (Figure 4b). Interest-
ingly, HA–D2 still underwent a serum-stimulated mobility
shift, suggesting that HA–D2 may be phosphorylated by a
mitogen-dependent MEK-independent kinase. 
RSK1 is phosphorylated by PDK1 and ERK in vitro
We have thus far demonstrated that isolated RSK1 kinase
domains can be activated in vivo. The signals responsible
for that activation have not been completely elucidated,
however. It is well established that ERK phosphorylation is
a critical event for RSK1 activation. ERK binds the RSK1
carboxyl terminus [2,25,26] and phosphorylates a site
within the activation loop of the carboxy-terminal kinase
domain [11]. Activated ERK also activates the RSK1
carboxy-terminal autophosphorylation activity in vitro [2].
Mutation of the putative ERK phosphorylation site in full-
length RSK1 reduces RSK1 amino-terminal kinase activity
towards exogenous substrate ([10]; data not shown), re-
inforcing the importance of this phosphorylation event. In
avian RSK1, this phosphorylation site is Thr590. When
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Figure 2
Activation of an isolated amino-terminal RSK kinase domain. HEK
293E cells were transfected with constructs expressing either wild-
type (WT) or K112R mutant versions of HA–D1 or HA–D1′ as
indicated. Starved cells were stimulated for 10 min and lysed as
described in Materials and methods. Lysates were blotted for D1 and
D1′ expression with an anti-HA antibody. Mobility shifting of
endogenous RSK was visualized by blotting with an anti-RSK antibody.
HA-tagged proteins were immunoprecipitated with an anti-HA
antibody, and immunoprecipitation kinase assays were performed
using GST–S6 as substrate. The graph shows quantitation of S6
phosphorylation using a phosphorimager. The results are
representative of three separate experiments.
Serum : – – – –+ + + +
D1′ D1
K112R K112RWT WT
Anti-HA
A
rb
itr
ar
y 
un
its
Anti-RSK
Current Biology   
0
20,000
40,000
60,000
80,000
Figure 3
Activation of an isolated carboxy-terminal RSK kinase domain. HEK
293E cells were transfected with constructs expressing wild-type
(WT) or the K464R mutant of HA–D2 as indicated. After stimulating
the starved cells for 10 min with serum, cells were lysed and subjected
to SDS–PAGE and western blotting. (a) Western blot with an anti-
RSK antibody showing shifting of endogenous RSK due to in vivo
phosphorylation upon serum stimulation. (b) Western blot with an anti-
HA antibody to show expression of HA–D2. (c) Kinase assay of
HA–D2 phosphotransferase activity. Transfected HA–D2 (WT) or
HA–D2 (K464R) was immunoprecipitated with an anti-HA antibody
and incubated with GST–D2 (K464R) and [γ-32P]ATP. Upper band,
phosphorylated exogenous substrate GST–D2 (K464R); lower band,
autophosphorylation of transfected HA–D2. (d) Quantitation of
HA–D2 phosphotransferase activity. Phosphotransferase activity
towards GST–D2 (K464R) and autophosphorylation of HA–D2 were
quantitated on a phosphorimager. The results are representative of
three separate experiments.
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GST–D2 (K464R) was used as a substrate for activated
ERK1 in an in vitro kinase reaction, it was found to be
phosphorylated (Figure 5a), but the phosphorylation was
eliminated when the substrate contained a T590A muta-
tion. We conclude that Thr590 in avian RSK1 is an ERK
phosphorylation site.
Signals required for the activation of the amino-terminal
kinase domain are less well understood, and are of particu-
lar interest as all exogenous RSK substrates are phosphory-
lated by this kinase domain. Four phosphorylation sites
have been identified within this region in rat RSK1 [10]. In
avian RSK1, these sites are Ser239, Thr377, Ser381 and
Ser398 (in rat RSK1, the corresponding sites are Ser222,
Thr360, Ser364 and Ser381). Sequence comparison sug-
gested that the Ser239 residue of avian RSK1 was either an
autophosphorylation site or a site phosphorylated by PDK1
([10]; Figure 5b). To test the hypothesis that PDK1 phos-
phorylates the RSK1 amino terminus, a GST–D1′ fusion
protein was made; a second GST–D1′ fusion protein carry-
ing a point mutation (S239A) at the putative PDK1 site was
also generated. When purified GST–D1′ (K112R) and
GST–D1′ (K112R, S239A) were used as substrates in an in
vitro kinase assay, only GST–D1′ (K112R) was phosphory-
lated by PDK1 (Figure 5c, upper panel); the S239A mutant
was not phosphorylated. The lack of phosphorylation in
the S239A mutant also indicated that the GST moiety was
not phosphorylated by PDK1. PDK1 was active in both
kinase reactions, as indicated by its autophosphorylation
(Figure 5c, lower panel). The kinase-inactive PDK1
(K110N) mutant did not phosphorylate D1′ (data not
shown). To compare the efficiency of RSK1 phosphoryla-
tion by Myc–PDK1 with a characterized PDK1 substrate,
in vitro kinase assays were performed using GST–D1 RSK
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Figure 4
The MEK inhibitor PD098059 affects HA–D1′ and HA–D2 activation.
HEK 293E cells were transfected with (a) HA–D1′ or (b) HA–D2 and
starved of serum. After a 30 min pretreatment with PD098059,
transfected cells were stimulated with serum where indicated. Cell
lysates were subjected to SDS–PAGE and quantitative western
blotting with an anti-HA antibody (lower panels). Volumes corrected for
equal HA–D1′ or HA–D2 expression were used in immunocomplex
kinase assays. (a) GST–S6 was used to assay HA–D1′ activity, and
(b) GST–D2 (K464R) was used to assay HA–D2 activity. Quantitation
was on a phosphorimager. The results are representative of four
separate experiments.
HA–D1′   Current Biology HA–D2
Anti-HA
A
rb
itr
ar
y 
un
its
A
rb
itr
ar
y 
un
its
GST–S6 GST–D2 (K464R)
0
20,000
40,000
60,000
80,000
0
5,000
10,000
15,000
20,000
(a) (b)
Serum
PD
– + – +
– – + +
– + – +
– – + +
Figure 5
RSK1 is phosphorylated by ERK and PDK1. (a) Phosphorylation of
GST–D2 by ERK. In vitro kinase assays were performed using a
bacterially expressed MEK-activated ERK1 (GST–ERK1*), or
GST–ERK1 (K52R). The mutated ERK residue is K52R, which
inactivates the ERK catalytic activity. The ERK fusion proteins were
incubated with [γ-32P]ATP and 1 µg of either GST–D2 (K464R, T590)
or GST–D2 (K464R, T590A). Autoradiography indicates that activated
ERK phosphorylated the T590 substrate but not the T590A mutant.
(b) Alignment of sequences phosphorylated by PDK1 with the putative
PDK1 phosphorylation site in RSK1 (adapted from [35]). Arrow
indicates the phosphorylated residue. (c) Phosphorylation of GST–D1′
by a fusion protein between PDK1 and the Myc epitope tag
(Myc–PDK1). Myc–PDK1 was immunoprecipitated from transfected
HEK 293E cells and used in an in vitro kinase assay with 1 µg
GST–D1′ (K112R) as substrate. Upper panel, phosphorylation of
GST–D1′ (K112R) and GST–D1′ (K112R, S239A) by Myc–PDK1;
lower panel, PDK1 autophosphorylation. (d) Phosphorylation of full-
length RSK by PDK1. Transfected HA–RSK (K112R, K464R) was
immunoprecipitated from quiescent 293 cells and used in an in vitro
kinase assay with 0.2 µg GST–PDK1 (WT) or GST–PDK1 (K110I) as
indicated, or 50% glycerol (lane 1). The mutated residue in
GST–PDK1 (K/I) is K110I. Autoradiography indicated that full-length
RSK (upper arrow) was phosphorylated in the presence of active
PDK1 (lower arrow), which autophosphorylates itself.
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and GST–PKCζ as substrates (see Supplementary mater-
ial). With equimolar amounts of substrate under linear
reaction conditions, Myc–PDK1 phosphorylated both
GST–D1 and GST–PKCζ, with PKCζ phosphorylation
slightly higher (1.5–2-fold) than GST–D1 RSK.
Finally, we examined the ability of PDK1 to phosphory-
late full-length RSK in vitro. A kinase-deficient RSK was
immunoprecipitated from quiescent cells and incubated
with GST–PDK1. As shown in Figure 5d, the full-length
protein was phosphorylated by PDK1 (lane 2) but not by a
kinase-deficient PDK1 (lane 3). Because this RSK fusion
protein was catalytically inactive, the RSK phosphoryla-
tion is not due to autophosphorylation activity.
The data presented above suggest that RSK is phosphory-
lated by PDK1, and that S239 in RSK1 is a PDK1 phos-
phorylation site. This is the first indication that a
regulatory input other than from ERK plays a role in
RSK1 activation.
PDK1 activates an isolated RSK1 amino-terminal kinase
domain
Because PDK1 phosphorylates the RSK1 amino terminus
in vitro, we tested the effect of PDK1 on D1′ activation in
vivo. HEK 293E cells were cotransfected with D1′ and
increasing amounts of either wild-type PDK1 or the kinase-
inactive PDK1 (K110N). Figure 6a shows that increasing
amounts of PDK1 increased D1′ kinase activity towards the
exogenous substrate. Surprisingly, D1′ activation by PDK1
alone approached the activation level induced by serum.
Coexpression of the kinase-inactive PDK1 (K110N) mutant
actually decreased basal D1′ kinase activity, a result consis-
tent with the finding that the S239 site is basally phos-
phorylated [10]. PDK1 (K110N) may reduce basal
phosphorylation at S239, thereby decreasing basal phospho-
transferase activity. These results suggest that PDK1 alone
can activate the RSK1 amino-terminal kinase domain.
Although the in vitro phosphorylation of D1′ by PDK1
suggests that the phosphorylation is direct, it is possible
that the overexpression of PDK1 could induce activation
of various PKCs, which could indirectly activate D1′
through the ERK/MAP kinase pathway. To address this
possibility, we expressed an S239A D1′ mutant in the
presence of PDK1 and a constitutively active MEK-1
protein in which serine residues 218 and 222 were substi-
tuted by aspartic acid residues (MEK-DD) and examined
mobility shifts; because a S239A mutation renders the
amino-terminal kinase domain inactive ([10]; data not
shown), kinase assays to examine the effect on activity
are not possible. Figure 6b shows that when S239 is
mutated to alanine in D1′, the doublet seen in the wild-
type protein is replaced by a single band of faster mobil-
ity. No mobility shift was seen in D1′ (S239A) upon
serum stimulation or cotransfection with PDK1 or MEK-
DD. For wild-type D1′, intensification of the upper band
was seen upon coexpression with PDK1 but not with
MEK-DD. While this result does not eliminate the possi-
ble indirect contribution of other kinases activated by
PDK1, it does suggest that the slower-migrating form of
D1′ is the result of basal phosphorylation, and that this
phosphorylation is not a direct result of activation of the
ERK/MAP kinase pathway.
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Figure 6
PDK1 activates an isolated RSK1 amino-terminal kinase domain.
(a) Activation of HA–D1′ by PDK1. The construct encoding HA–D1′
(1 µg) was cotransfected with the indicated amounts of construct
encoding wild-type or K110N mutant of PDK1. Transfected cells
were starved or stimulated with serum as indicated. Cell lysates were
subjected to SDS–PAGE and transferred to nitrocellulose.
Quantitative western blots were performed using an anti-HA
antibody, which detected HA–D1′. Upper panel, volumes corrected
for HA–D1′ expression levels were used in anti-HA antibody
immunocomplex assays, using GST–S6 as substrate (see Materials
and methods; the autoradiogram was quantitated by phosphorimager
analysis); lower panel, HA–D1′ expression before correction for
equivalent protein expression. The results are representative of three
separate experiments. (b) Effect of PDK1 and MEK-DD on HA–D1′
(S239A). Constructs (1 µg) encoding wild-type HA–D1′ or the
S239A mutant were cotransfected with the indicated amounts of
PDK1 or MEK-DD, starved or stimulated with serum as indicated, and
subjected to SDS–PAGE. Western blots were performed with
antibodies against the avian RSK epitope or Myc to detect
transfected D1′ and PDK1, respectively.
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PDK1 is not sufficient to activate full-length RSK1
We have established that PDK1 alone can activate phos-
photransferase activity of the isolated amino-terminal
kinase domain of RSK1, and we next investigated the effect
of PDK1 on full-length RSK1, which carries both kinase
domains. HEK 293E cells were cotransfected with full-
length RSK1 and PDK1 (Figure 7a), and RSK1 activity was
assayed. At higher expression levels, PDK1 induced a small
activation of RSK1 kinase activity, but did not approach the
level induced by serum. Under these conditions, immuno-
precipitated Myc–PDK1 coprecipitated HA–RSK1, as
detected by western blotting, indicating that the two pro-
teins are interacting (Figure 7c). RSK activation was slightly
enhanced upon coexpression of PDK1 with RSK in serum-
stimulated cells, although fold-activation was slightly lower,
possibly as a result of higher basal activity (Figure 7b).
Although PDK1 could phosphorylate full-length RSK1 in
vitro (Figure 5d), it was possible that PDK1 did not regu-
late the phosphorylation of full-length RSK1 in vivo. To
examine this possibility we took advantage of the observa-
tion that phosphorylation of wild-type full-length RSK
affects its mobility in SDS–polyacrylamide gels [27]. In
quiescent cells, RSK1 existed primarily as a faster-migrat-
ing species but, upon activation by serum, slower-migrat-
ing middle and upper bands were observed (Figure 8a).
Coexpression with PDK1 in the absence of serum induced
a shift in wild-type RSK1 to the middle band, implying
that full-length RSK1 can be phosphorylated upon coex-
pression with PDK1. A shift to the uppermost band was
never observed, however.
To confirm that PDK1 induced a mobility shift in full-
length RSK1 in vivo, an S239A mutation was introduced
into full-length RSK1. This mutation renders the phos-
photransferase activity of the RSK1 amino-terminal kinase
domain inactive ([10]; data not shown). When RSK1
(S239A) was expressed in cells, serum stimulation was still
able to induce a shift to the slower-migrating band
(Figure 8a); in the absence of serum, however, PDK1 did
not induce a shift to a slower-migrating species. This is in
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Figure 7
PDK1 alone does not activate full-length RSK1. (a) Effect of PDK1 on
RSK1 activation in vivo. The construct encoding full-length HA–RSK1
(1 µg ) was cotransfected with the indicated amounts of construct
encoding Myc–PDK1. Transfected cells were starved or stimulated
with serum as indicated. Cell lysates were subjected to SDS–PAGE
and transferred to nitrocellulose. Quantitative western blots were
performed using an anti-HA antibody to detect full-length HA–RSK1.
Samples with volumes adjusted to obtain equal HA–RSK1 expression
were used in anti-HA antibody immunocomplex assays with GST–S6
as substrate. Upper panel, HA–RSK1 kinase activity measured by
immunocomplex assay; lower panels, western blots showing
expression of HA–RSK1 and Myc–PDK1 as indicated. The results are
representative of three separate experiments. (b) Effect of PDK1 on
serum-stimulated RSK1 activity. The construct encoding full-length
HA–RSK (1 µg) was transfected alone or with 2 µg plasmid
expressing Myc–PDK1 as indicated. Transfected cells were starved or
stimulated with serum as indicated. HA–RSK was immunoprecipitated
with an anti-HA antibody for immunocomplex assays using GST–S6 as
substrate (upper panel). Western blots (lower panels) were performed
with antibodies against the avian RSK epitope or Myc to detect
transfected full-length RSK or PDK1, respectively. The results are
representative of two separate experiments. (c) RSK1 and PDK1
interact in vivo. HA–RSK1 and Myc–PDK1 were cotransfected as in
(a). Myc–PDK1 was immunoprecipitated from cell lysates [38] and
subjected to SDS–PAGE. Western blotting with antibodies against
the avian RSK epitope detected RSK1 associated with Myc–PDK1.
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contrast to the shift induced in wild-type RSK1 under
these conditions. These data suggest that, although PDK1
does not activate full-length wild-type RSK1, it is capable
of inducing RSK1 phosphorylation in vivo.
The serum-induced shift in RSK1 (S239A) could be the
result of phosphorylation of the carboxyl terminus and
autophosphorylation by this activated carboxy-terminal
kinase domain. The amino-terminal kinase domain is inac-
tive [10], but to test whether the carboxy-terminal kinase
domain of this mutant was active, kinase assays were per-
formed with immunoprecipitated RSK1 (S239A), using
GST–D2 (K464R) as substrate. As seen again in Figure 8b,
RSK1 (S239A) underwent a shift upon serum stimulation
(lower panel). This shift correlated with both the ability of
the carboxyl terminus to phosphorylate the exogenous sub-
strate (upper panel) and the ability to autophosphorylate
(data not shown). To examine whether the activation of
the carboxy-terminal kinase domain was solely due to ERK
phosphorylation, RSK1 (S239A) was coexpressed with
increasing amounts of MEK-DD. While coexpression with
MEK-DD induced a mobility shift in the S239A mutant of
RSK1 (lower panel), it was not sufficient to activate
carboxy-terminal-domain kinase activity towards GST–D2
(K464R) — the exogenous substrate (upper panel) — or
for autophosphorylation (data not shown). These results
suggest that, for RSK1 (S239A), inactivation of the amino-
terminal kinase domain does not affect the ability of the
carboxy-terminal kinase domain to be activated by mito-
genic stimuli such as serum, nor does it block presumed
autophosphorylation. Nevertheless, full activation of the
RSK1 carboxyl terminus requires inputs in addition to
ERK, either by autophosphorylation by the amino-termi-
nal kinase domain or by other mitogen-activated kinases.
MEK-DD and PDK1 cooperate to activate full-length RSK1
RSK1 activation requires interaction between the RSK1
carboxyl terminus and ERK [25], and blocking MEK acti-
vation with PD098059 decreases RSK1 activation [28]. We
therefore examined the possibility that both ERK and
PDK1 are required for RSK1 activation. To do this, RSK1
activity was first assayed upon coexpression with increas-
ing amounts of MEK-DD in HEK 293E cells; MEK-DD
causes constitutive activation of ERK [29]. As seen in
Figure 9, higher doses of MEK-DD could significantly
activate RSK1 phosphotransferase activity. To investigate
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Figure 8
Serum-stimulated activation of the RSK carboxyl terminus is
independent of phosphorylation at Ser239. (a) Western blot showing
mobility shift of RSK1 when co-expressed with PDK1. Plasmids
encoding wild-type RSK1 or the S239A mutant (1 µg of either) were
cotransfected with increasing amounts of the construct for Myc–PDK1.
Transfected cells were starved or stimulated with serum as indicated.
Cell lysates were probed for expression of RSK1 (using the antibody
against the avian-specific epitope) and PDK1 (using anti-Myc antibody).
(b) The carboxy-terminal kinase domain of RSK1 (S239A) is activated
by serum. The construct for the S239A mutant of RSK1 (1 µg) was
cotransfected with increasing amounts of plasmid encoding MEK-DD.
The western blot (lower panel) shows that serum and MEK-DD induce
a shift in mobility of RSK1 (S239A). An immunocomplex kinase assay
performed using the antibody against the HA epitope, and GST–D2
(K464R) as substrate, showed activation of phosphotransferase activity
of the carboxy-terminal kinase domain (upper panel). The results are
representative of two separate experiments.
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Figure 9
RSK1 activation by MEK-DD. Plasmid (1 µg) encoding HA–RSK1 was
transfected with increasing amounts of plasmid encoding MEK-DD.
Transfected cells were starved or stimulated with serum as indicated.
Cell lysates were subjected to SDS–PAGE and transferred to
nitrocellulose. RSK1 expression was detected using the antibody
against the avian-specific RSK epitope. The graph shows RSK1
immunocomplex assays using GST–S6 as substrate, performed as
described in Materials and methods. The results are representative of
two separate experiments.
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whether there was a co-operative effect with PDK1, subac-
tivating levels of MEK-DD were chosen: 0.25 and 0.5 µg.
We then expressed full-length RSK1 with both MEK-DD
and PDK1. As seen above and in Figure 10, expression of
wild-type RSK1 with either MEK-DD (lanes 3,6) or PDK1
alone (lanes 9,10) did not significantly activate RSK1
kinase activity. When MEK-DD and PDK1 were co-
expressed, however, RSK1 phosphorylation of GST–S6
was activated at a level higher than with either PDK1 or
MEK-DD alone (lanes 4,5 and 7,8), and this activation was
dose dependent. Therefore, MEK-DD and PDK1 cooper-
atively activate RSK1.
Discussion
Activation of RSK1 has been thought to be dependent
solely on phosphorylation by activated ERK and subse-
quent RSK1 autophosphorylation. We have shown here
that PDK1 phosphorylates wild-type avian RSK1 and is
even capable of activating the isolated RSK1 amino-termi-
nal kinase domain. Furthermore, cooperation between
ERK and PDK1 can produce an active RSK1 enzyme.
The contribution of PDK1 means that we have uncovered
an additional signaling pathway involved in the regulation
of RSK1. 
That phosphorylation by ERK is critical for RSK1 activa-
tion is indisputable. The observation that mutation of the
ERK phosphorylation site in the RSK1 carboxyl terminus
severely compromises mitogen-stimulated RSK1 kinase
activity ([10]; data not shown) reinforces this supposition.
Preventing ERK activation by inhibiting upstream MEK
with PD098059 blocks RSK1 activation [28]. There have
been indications, however, that ERK is not sufficient for
full activation of RSK1; activation of quiescent RSK
in vitro with activated ERK restores only a portion of
RSK1 phosphotransferase activity [30]. Although we have
shown here that an isolated amino-terminal RSK1 kinase
domain is readily activated by PDK1, this contribution
would be masked in the full-length protein because of the
requirement for ERK in RSK1 activation. The role of
PDK1 would be concealed under conditions where ERK
is quiescent. We propose a model for RSK1 activation that
incorporates the requirements for phosphorylation by
ERK and PDK1, as well as other activating phosphoryla-
tion events (Figure 11).
The PDK1 phosphorylation site identified here in RSK1
is preserved in all three human RSK isoforms: RSK1,
RSK2, and RSK3 [31]. In a patient diagnosed with
Coffin–Lowry syndrome, the PDK1 phosphorylation site
is mutated in RSK2, and several patients lack active RSK2
[32]. Coffin–Lowry syndrome is characterized by mental
retardation, various musculoskeletal defects and motor
difficulties. This suggests that RSK enzyme activity could
be involved in normal development. 
The RSK carboxy-terminal kinase domain is homologous
to the mitogen- and stress-activated protein kinases
MNK1 and MNK2, which are also phosphorylated by
ERK [33,34]. We have previously shown that the RSK
carboxy-terminal kinase domain is active in vitro [2]. Here,
we have extended the characterization to demonstrate that
the catalytic activity exhibited by this kinase domain is
regulated in vivo in response to growth stimuli. 
The RSK amino-terminal kinase domain is homologous to
the kinase domains in other members of the AGC family,
which includes PKA, various PKCs, and p70S6K1
(Figure 5b; reviewed in [35]). The PDK1 phosphorylation
site in RSK1 is similar to PDK1 sites in these other
enzymes, suggesting that this a general regulatory site for
these kinases. Using immunoprecipitated PDK1, similar
levels of in vitro phosphorylation were seen with equimo-
lar amounts of GST–D1 (K112R) and GST–PKCζ, a
known PDK1 substrate (data not shown). This site was
found to be basally phosphorylated in RSK1, with a
further increase in phosphorylation upon stimulation with
phorbol myristoyl acetate [10]. This basal phosphorylation
is consistent with our observations that D1′ has high basal
activity relative to the serum-stimulated activity level, and
that expression of a kinase-inactive PDK1 can decrease
D1′ basal phosphotransferase activity.
Although PDK1 does phosphorylate Akt/PKBα, p70S6K1
and RSK1, there are differences in the phospholipid
requirement for this phosphorylation. For Akt/PKBα, this
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Figure 10
PDK1 and MEK-DD cooperate to activate RSK1. The construct
encoding HA–RSK1 (1 µg plasmid) was transfected with the indicated
amounts of plasmids for Myc–PDK1 and MEK-DD. Transfected cells
were starved or stimulated with serum as indicated. Western blots
were probed with an antibody against the HA epitope tag and
subjected to quantitative enhanced chemiluminescence (ECL) and
corrected levels were used for RSK1 anti-HA antibody
immunocomplex assays, using GST–S6 as a substrate (upper panel).
The lower panel shows expression of HA–RSK1 and Myc–PDK1. The
results are representative of four separate experiments.
Serum
Myc–PDK1 (µg)
MEK-DD (µg)
  Current Biology
0.25 0.5 
Anti-HA–RSK
Anti-Myc–PDK1
A
rb
itr
ar
y 
un
its
1 2 3 4 5 6 7 8 9 10
– + – – – – – – – –
0 0
0 0 0 0
0 2.5 2 0 0.5 2 0.5 2
0
25,000
50,000
75,000
100,000
reaction is dependent on phospholipids [15,16,36,37].
Binding of phosphatidylinositol 3,4-bisphosphate
(PtdIns(3,4)P2) or PtdIns(3,4,5)P3 to the PH domain of
Akt/PKBα, targets the enzyme to the membrane and
brings it into proximity with membrane-associated PDK1.
Phosphorylation of p70S6K1 by PDK1 is independent of
phospholipids [21,22], and the ability of PDK1 to phos-
phorylate RSK1 in vitro suggests that this reaction is also
phospholipid independent. 
There are also differences in how PDK1 collaborates with
different inputs to fully activate a kinase. With
Akt/PKBα, it has been suggested that accessibility of the
PDK1 phosphorylation site is regulated by binding of
PtdIns(3,4)P2/PtdIns(3,4,5)P3 to the Akt/PKBα PH
domain [23]. This induces a conformational change, ren-
dering the PDK1 site on Akt/PKBα accessible. With
p70S6K1, PDK1 cooperates with Rho family GTPases, PI
3-kinase, and inputs regulated by mTOR or FK506-
binding protein (FKBP)–rapamycin associated protein
(FRAP) ([38]; data not shown). PDK1 phosphorylation
and activation of p70S6K1 requires prior phosphorylation of
residues in the p70S6K1 regulatory domain [22]. In this
case, phosphorylation is used instead of phospholipid
binding to achieve the same goal: a conformational change
exposing a PDK1 phosphorylation site. 
Here, we have shown that RSK1 activation requires coop-
eration between the Ras–ERK/MAP kinase pathway and
PDK1. RSK1 is unique in that activation of one kinase
domain requires activation of another. Nature has solved
the problem of bringing these two kinases together by
fusing the RSK carboxy-terminal kinase domain (homolo-
gous to MNK1/MNK2) to the amino-terminal kinase
domain (homologous to the AGC superfamily of kinases).
Activation of RSK1 phosphotransferase activity towards
exogenous substrates necessitates the convergence of the
two signaling pathways, with each kinase domain requir-
ing a different signal: the carboxy-terminal kinase domain
requires phosphorylation by ERK, and the amino-terminal
kinase domain requires phosphorylation by PDK1.
Full-length RSK1 and PDK1 can be coimmunoprecipi-
tated from quiescent cells, suggesting that they interact
in vivo. The phosphorylation of quiescent full-length
RSK1 by PDK1 without activating the amino-terminal
kinase domain suggests that the PDK1 site in RSK1 is
accessible. This phosphorylation is quite different from
PDK1 phosphorylation of Akt/PKBα and p70S6K1. In this
regard, RSK1 may be similar to PKA, whose basal phos-
phorylation at the PDK1 site is co-translational
[20,39,40]. If this were also the case for RSK1, it may
explain the inability of a dominant-negative PDK1 to
antagonize serum-stimulated RSK1 activation (data not
shown). We also suggest that, when quiescent, the RSK1
carboxyl terminus acts as a negative regulator of the
amino-terminal kinase domain. We have shown here that
phosphotransferase activity of the isolated RSK1 amino-
terminal kinase domain can be activated by PDK1 alone,
but the full-length RSK1 cannot; activation of full-length
RSK1 requires activated ERK.
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Figure 11
Model of RSK1 activation by PDK1 and ERK. We propose that PDK1
phosphorylates RSK1, even when RSK1 is quiescent. The RSK1
carboxyl terminus acts as a negative regulator, blocking activation of
the amino-terminal kinase domain. Upon mitogen stimulation, ERK
becomes activated and phosphorylates the RSK1 carboxyl terminus.
This phosphorylation activates the RSK1 carboxy-terminal kinase
domain and stimulates RSK1 autophosphorylation by this domain.
Activation of the carboxy-terminal kinase domain induces a
conformational change, abrogating the negative regulatory effect of
this domain. The RSK1 amino-terminal kinase domain is then freed to
phosphorylate exogenous substrates. P, phosphate groups.
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Although we have demonstrated that phosphorylation by
PDK1 and ERK are necessary and sufficient for RSK1 acti-
vation, we have not eliminated the possibility of additional
activating signals. Activation by MEK-DD and PDK1 does
not activate RSK1 to levels attained by serum stimulation,
and full activation of the RSK1 carboxyl terminus requires
signals in addition to phosphorylation by ERK. The amino-
terminal kinase domain is likely to be important, as are the
additional RSK1 phosphorylation sites. The inhibition of
D1′ kinase activity by PD098059 indicates that this kinase
domain is regulated by the ERK/MAP kinase pathway,
either directly or indirectly. Additional sites for phosphory-
lation by ERK have been suggested within this domain
[10]. In addition, S398, which has been identified as a RSK
autophosphorylation site [12] is a consensus sequence for
PDK2 phosphorylation [41]. 
Further studies addressing the autoregulation of the indi-
vidual kinase domains and the interactions between RSK1
and regulatory kinases will be important for understanding
the regulatory role of other RSK1 phosphorylation sites.
The data presented here support a role for an ERK-inde-
pendent event in regulating RSK1 kinase activity. This
finding introduces both new clarity and increased com-
plexity in understanding the role of RSK1 in cell prolifera-
tion and survival signaling.
Conclusions
PDK1 and ERK act cooperatively to activate phospho-
transferase activity of the serine/threonine kinase RSK1.
Our results show that, in addition to having an important
role in signaling to kinases regulated by PI 3-kinase,
PDK1 also participates in Ras–ERK/MAP kinase signaling
through RSK1.
Materials and methods
Plasmid constructs
Avian RSK1 was subcloned into pKH3, which encodes a triple HA tag
at the amino terminus [42]. Avian RSK1 contains an avian-specific
epitope between amino acids 37 and 54. The S239A mutant was gen-
erated using Stratagene’s QuikChange kit. D1, D1′ and D2 in pKH3
were generated by PCR. D1′ (K112R) in pGEX-2T was generated by
PCR using avian RSK1 (K112R) as target, and this was then used as
target DNA for PCR-based site-directed mutagenesis to generate the
D1′ (K112R, S239A) in pGEX-2T. A similar strategy was used to gen-
erate GST–D2 (K464R) with and without the T590A mutation. MEK-
DD in pCDNA3 was a gift from R. Erikson. Wild-type and K110N
versions of Myc–PDK1 in pCDNA3 were previously described [17].
Cell culture, transfection and lysis
HEK 293E cells were grown in DME with 10% FBS in 6% CO2. Cells
were transfected with CaPO4 for 5 h with 1 µg RSK with a total of 5 µg
DNA per 60 mm dish unless otherwise indicated; DNA quantities were
equalized with empty vector pRK7. Cells were rinsed with PBS and
starved in DME without serum for 16 h. Where indicated, cells were
stimulated with 10% calf serum at 37°C, 6% CO2 for 10 min. Cells
were rinsed with PBS on ice before lysis in cell-lysis buffer (10 mM
KPO4, 1 mM EDTA, 5 mM EGTA, 10 mM MgCl2, 50 mM β-glycerophos-
phate, 0.5% NP-40, 0.1% Brij-35, 0.1% deoxycholic acid, 1 mM sodium
orthovanadate, 2 mM DTT, 1 mM PMSF, 5 µg/ml pepstatin and
10 µg/ml leupeptin). Lysates were centrifuged at 14,000 rpm at 4°C for
10 min before separating into aliquots and storage at –80°C.
Western blotting
Lysates were subjected to SDS–PAGE and transferred to nitrocellulose.
The filter was blocked with 3% milk/TBS-Tween for 1 h at room temper-
ature. Primary antibody treatment was for 1 h at room temperature. Poly-
clonal antibody against the RSK1 avian-specific epitope (1:5,000), and
polyclonal anti-RSK1 (1:500) and anti-MAP kinase (1:2,000) antibodies
were generated as described [2]. Anti-HA (1:60,000) and anti-Myc
(1:2,000) antibodies were used where indicated. Blots were washed
with TBS-T before treatment with either goat anti-mouse HRP (1:30000
for quantitative ECL) and anti-rabbit HRP (1:5,000) for 1 h at room tem-
perature. Blots were visualized by ECL (NEN) or quantitated by ECL on
a BioRad FluorS with BLAZE ECL reagents (Pierce).
Immunoprecipitation kinase assays
For RSK1 kinase assays, antibody to the HA epitope tag was added to
cell lysates and incubated at 4°C for 2 h. Immunoprecipitation kinase
assays with GST–S6 were performed as described [43]. Because the
RSK1 carboxy-terminal kinase domain does not phosphorylate
GST–S6, GST–D2 (K464R) was used as a substrate to assay
carboxy-terminal kinase activity of RSK1. For MAP kinase kinase
assays, anti-MAP kinase antibody was added to lysates and the assay
was performed as for anti-RSK1 antibody assays except using
GST–D2 (K464R) as substrate [2]. Reactions were subjected to
SDS–PAGE and quantitated on a BioRad Phosphorimager.
In vitro kinase assays
Substrate GST fusion proteins were purified with glutathione–sepharose
beads (Pharmacia). For in vitro ERK phosphorylation, GST–ERK* and
GST–ERK K52R* were activated with MEK1 and purified [2]. For in vitro
PDK1 phosphorylation, Myc–PDK1 was immunoprecipitated from tran-
siently transfected HEK 293E cells and washed once each with buffer A
(10 mM Tris pH 7.2, 1% NP-40, 0.5% sodium deoxycholate, 100 mM
NaCl, 1 mM EDTA, 0.5% sodium orthovanadate, 2 mM DTT, 100 mM
PMSF), buffer B (same as buffer A except 0.1% NP-40 and 1 M NaCl),
and ST (50 mM Tris-HCl, 5 mM Tris-Base, 150 mM NaCl) before resus-
pension in kinase buffer [43]. All reactions were carried out with 10 µCi
[γ-32P]ATP (NEN) per reaction at 30°C for 15 min. Before stopping the
Myc–PDK1 reactions, samples were placed on ice and centrifuged
10 min at 14,000 × g at 4°C to precipitate Myc–PDK1. Supernatant and
pellet fractions were run separately. Reactions were resolved by
SDS–PAGE and exposed to film.
Supplementary material
Supplementary material, including in vitro kinase assays performed
using GST–D1 RSK and GST–PKCζ as substrates, is available at
http://current-biology.com/supmat/supmatin.htm.
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S1Supplementary material
Figure S1
In vitro phosphorylation of GST–D1 K112R with GST–PKCζ (Z) by
Myc–PDK1. HEK 293E cells were transfected for 5 h with 1 µg
Myc–PDK1, rinsed and recovered in DMEM containing 10% foetal
bovine serum. After 16 h, cells were lysed and treated with an anti-Myc
antibody to precipitate Myc–PDK1. The indicated amounts of
GST–substrate were added to PDK1 immunoprecipitates in an in vitro
kinase reaction that contained [γ-32P]ATP. After 20 min at 30°C,
reactions were placed on ice and spun at 14,000 x g for 10 min at
4°C. Sample buffer was added to the supernatant, which was then
separated by SDS–PAGE. Phosphate incorporation was quantitated
on a phosphorimager. The data show that MycPDK1 phosphorylates
GST–D1 K112R and GST–PKCζ at comparable levels in vitro.
Results are representative of two separate experiments.
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